Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer

Jeremy R. Chien, Giovanni Aletti, Debra A. Bell, Gary L. Keeney, Viji Shridhar, Lynn C. Hartmann

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance.

Original languageEnglish (US)
Pages (from-to)1117-1129
Number of pages13
JournalJournal of Cellular Biochemistry
Volume102
Issue number5
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Carcinogenesis
Neoplasm Metastasis
Chemotherapy
Cause of Death
Neoplasms
Recurrence
Drug Therapy
Therapeutics
Ovarian epithelial cancer

Keywords

  • Molecular pathogenesis
  • Ovarian cancer
  • Therapeutic targets

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Chien, J. R., Aletti, G., Bell, D. A., Keeney, G. L., Shridhar, V., & Hartmann, L. C. (2007). Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. Journal of Cellular Biochemistry, 102(5), 1117-1129. https://doi.org/10.1002/jcb.21552

Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. / Chien, Jeremy R.; Aletti, Giovanni; Bell, Debra A.; Keeney, Gary L.; Shridhar, Viji; Hartmann, Lynn C.

In: Journal of Cellular Biochemistry, Vol. 102, No. 5, 01.12.2007, p. 1117-1129.

Research output: Contribution to journalReview article

Chien, JR, Aletti, G, Bell, DA, Keeney, GL, Shridhar, V & Hartmann, LC 2007, 'Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer', Journal of Cellular Biochemistry, vol. 102, no. 5, pp. 1117-1129. https://doi.org/10.1002/jcb.21552
Chien, Jeremy R. ; Aletti, Giovanni ; Bell, Debra A. ; Keeney, Gary L. ; Shridhar, Viji ; Hartmann, Lynn C. / Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. In: Journal of Cellular Biochemistry. 2007 ; Vol. 102, No. 5. pp. 1117-1129.
@article{8e4b16c5bc444f22965e2573f25b7e68,
title = "Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer",
abstract = "Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance.",
keywords = "Molecular pathogenesis, Ovarian cancer, Therapeutic targets",
author = "Chien, {Jeremy R.} and Giovanni Aletti and Bell, {Debra A.} and Keeney, {Gary L.} and Viji Shridhar and Hartmann, {Lynn C.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1002/jcb.21552",
language = "English (US)",
volume = "102",
pages = "1117--1129",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer

AU - Chien, Jeremy R.

AU - Aletti, Giovanni

AU - Bell, Debra A.

AU - Keeney, Gary L.

AU - Shridhar, Viji

AU - Hartmann, Lynn C.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance.

AB - Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance.

KW - Molecular pathogenesis

KW - Ovarian cancer

KW - Therapeutic targets

UR - http://www.scopus.com/inward/record.url?scp=36849051967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849051967&partnerID=8YFLogxK

U2 - 10.1002/jcb.21552

DO - 10.1002/jcb.21552

M3 - Review article

C2 - 17879946

AN - SCOPUS:36849051967

VL - 102

SP - 1117

EP - 1129

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 5

ER -